Skip to main content

Multiplex PCR Testing Solution for Joint Infections

Authorized by the FDA through a De Novo authorization! The BIOFIRE® Joint Infection (JI) Panel targets a menu of 31 pathogens and 8 antimicrobial resistance markers—all in one test, with results in about an hour.

1 Syndromic Test. 39 Targets. About 1 Hour.

BIOFIRE's syndromic approach targets a comprehensive grouping of pathogens in one quick and easy test. The BIOFIRE JI Panel uses multiplex PCR technology to rapidly and accurately detect pathogens and resistance markers at the molecular level. Additionally, the BIOFIRE JI Panel requires only 0.2mL of synovial fluid.

View a full view of the BIOFIRE JI Panel pathogen menu.

Clinical Burden of Joint Infections

Joint infections are associated with significant morbidity and mortality rates, and prosthetic joint infections are on the rise.1 Joint infections are also notoriously challenging to diagnose, and successful treatment relies on the optimal selection of antibiotics.

Frequently employed tests for the diagnosis of joint infections are time-consuming, labor-intensive, and can lack sensitivity. Joint infections are often caused by anaerobic bacteria that can take weeks to grow in culture. While healthcare providers wait for slow culture results, patients are treated with empiric antibiotics, which may fail to adequately treat the infection and contributes to the growing threat of antimicrobial resistance.

Potential Benefits of the BIOFIRE Joint Infection Panel2

Compared to the standard of care, the BIOFIRE JI Panel may provide a faster and more straightforward method of diagnosing joint infections. Rapid results may help inform surgical decision making and optimal antibiotic selection. Because the BIOFIRE JI Panel accurately detects some organisms that are often missed by culture, it is likely to increase the diagnostic yield when used in conjunction with standard-of-care methods. The inclusion of antibiotic resistance genes can help healthcare providers optimize therapy sooner and avoid unnecessary antibiotic prescriptions.

Since 2018, prospective clinical evaluations of the BIOFIRE JI Panel have been conducted worldwide. These evaluations have shown a high sensitivity and specificity for target organisms and antimicrobial resistance genes. Overall, the BIOFIRE JI Panel claims about 91.7% sensitivity and 99.8% specificity.3

With a panel menu of 39 targets, the BIOFIRE JI Panel aims to accompany culture-based diagnostics for joint infections. Results are intended to be used in conjunction with other existing data and not as the sole basis for diagnosis and treatment.

How to Learn More About Syndromic Testing from BIOFIRE

References

  1. Tande A and Patel R. Clin Microbiol Rev. 2014 Apr; 27(2): 302-345.
  2. Multiplex PCR Panels for Joint Infections on the Horizon. Genome Web. Nov 6, 2020. https://www.genomeweb.com/pcr/multiplex-pcr-panels-joint-infections-horizon#.YCNS0ZNKj0t
  3. Graue C, et al. Evaluation of the BIOFIRE® Bone and Joint Infection (BJI) Panel for the Detection of Microorganisms and Antimicrobial Resistance Genes in Synovial Fluid Specimens. IDWeek 2020; Virtual.

SHARE THIS ARTICLE:

  • Diagnostic Digest